Major drugmakers are using artificial intelligence to find patients for clinical trials quickly, or to reduce the number of people needed to test medicines, both accelerating drug development and potentially saving millions of dollars.

Srivastava discusses how his personal upbringing eventually intersected with a team that works to deliver over 90% of FDA-approved therapeutic drugs onto the global market.

The New York-based company has been pressured by declining demand for two of its top drugs, the blood cancer treatment Revlimid and blood thinner Eliquis, which face generic competition.

Through its collaboration with the Oracle Cerner LHN, Syneos Health’s objective is to improve performance throughout the entire clinical trial lifecycle, with a strong emphasis on clinical trial enrollment to help close diversity gaps in patient recruitment.

Let’s think of this Barbie phenomenon as a catalyst to put women’s health and well-being at the forefront. How can we, as pharma marketers, keep the momentum going?

In Genethon’s Thursday announcement, the company claimed the results are the first clinical demonstration of the efficacy of gene therapy in a metabolic disease of the liver.

Following a handful of clinical failures and changes to its leadership, FibroGen is trying to chart a more positive path forward by focusing on four strategic areas.

Following several clinical failures for its candidates Roxadustat and pamrevlumab, FibroGen CEO Enrique Conterno is stepping down for “personal reasons,” the company announced Tuesday.

The program—a joint initiative between CDER and CBER—aims to accelerate the development of therapies for rare diseases.

The sale of the drug could be announced in the coming days, the report said, citing people familiar with the matter. The talks could still fall apart and another suitor could swoop in, it added.